Wooseob Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wooseob Kim has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Ali H. Ellebedy
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, USA
14 shared publications - Aaron J. Schmitz
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, USA
11 shared publications - Rachel M. Presti
Department of Medicine, Washington University School of Medicine, St Louis, USA
10 shared publications - Michael S. Diamond
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
8 shared publications Alem Haile
7 shared publications- Jane A. O'HAlloran
Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA
7 shared publications
Latest Publications
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadu4107
Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization
Germinal centers (GCs) are key sites for antibody diversification and affinity maturation. SARS-CoV-2 messenger RNA (mRNA) vaccines elicit robust GC B cell responses in humans, but how these responses influence the breadth of immunity against viral variants remains unclear. We analyzed GC B cell responses in nine healthy adults after mRNA booster immunization. We show that 77.8% of the B cell clones in the GC expressed representative monoclonal antibodies (mAbs) recognizing the spike protein, with 37.8% of these targeting the receptor binding domain (RBD). One RBD-targeting mAb, mAb-52, neutralized all tested SARS-CoV-2 strains, including the recent XEC variant. mAb-52 used the IGHV3-66 public clonotype, protected hamsters challenged against the EG.5.1 variant, and targeted the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Its broad reactivity was driven by extensive somatic hypermutation, underscoring the critical role of GC reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadu4107
Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization
Germinal centers (GCs) are key sites for antibody diversification and affinity maturation. SARS-CoV-2 messenger RNA (mRNA) vaccines elicit robust GC B cell responses in humans, but how these responses influence the breadth of immunity against viral variants remains unclear. We analyzed GC B cell responses in nine healthy adults after mRNA booster immunization. We show that 77.8% of the B cell clones in the GC expressed representative monoclonal antibodies (mAbs) recognizing the spike protein, with 37.8% of these targeting the receptor binding domain (RBD). One RBD-targeting mAb, mAb-52, neutralized all tested SARS-CoV-2 strains, including the recent XEC variant. mAb-52 used the IGHV3-66 public clonotype, protected hamsters challenged against the EG.5.1 variant, and targeted the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Its broad reactivity was driven by extensive somatic hypermutation, underscoring the critical role of GC reactions in shaping cross-variant B cell immunity after SARS-CoV-2 booster vaccination.
- 15 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (2) , e70322
Bacterial components‐driven intrahepatic CXCR5 hi B cells are important population for MASH progression through inducing inflammation
Metabolic dysfunction‐associated steatohepatitis (MASH) is characterized by severe liver inflammation and fibrosis due to an imbalanced immune response caused by enhanced bacterial components. The progression of MASH is closely linked to increased permeability of intestinal mucosal barrier facilitating enter of bacterial components into hepatic portal venous system. B cells are important immune cells for adaptive responses and enhance hepatic inflammation through cytokine production and T cell activation. B cells are influenced by gut microbiota, but the specific B cell populations in MASH and their pathologic mechanism remain obscure. Here, we found that the numbers of B cells highly expressing CXCR5, the receptor of CXCL13 chemokine, were increased in the livers of MASH. CXCR5 high B cells are non‐proliferating naive B cells with inflammatory features mainly residing in hepatic parenchyma to affect liver pathology. Importantly, we revealed that CXCR5 high B cells were induced by bacterial components stimulating TLRs. These bacterial stimulator‐induced CXCR5 hi B cells highly express TNFα, CD80, and MHC class II, leading to T cell activation. Consistently, we confirmed that intravenous injection of CXCR5 high B cells enhanced hepatic inflammation in MASH model. Ultimately, this study elucidates the role and mechanisms of CXCR5 high B cells in advancing MASH progression.
- 15 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (2) , e70322
Bacterial components‐driven intrahepatic CXCR5 hi B cells are important population for MASH progression through inducing inflammation
Metabolic dysfunction‐associated steatohepatitis (MASH) is characterized by severe liver inflammation and fibrosis due to an imbalanced immune response caused by enhanced bacterial components. The progression of MASH is closely linked to increased permeability of intestinal mucosal barrier facilitating enter of bacterial components into hepatic portal venous system. B cells are important immune cells for adaptive responses and enhance hepatic inflammation through cytokine production and T cell activation. B cells are influenced by gut microbiota, but the specific B cell populations in MASH and their pathologic mechanism remain obscure. Here, we found that the numbers of B cells highly expressing CXCR5, the receptor of CXCL13 chemokine, were increased in the livers of MASH. CXCR5 high B cells are non‐proliferating naive B cells with inflammatory features mainly residing in hepatic parenchyma to affect liver pathology. Importantly, we revealed that CXCR5 high B cells were induced by bacterial components stimulating TLRs. These bacterial stimulator‐induced CXCR5 hi B cells highly express TNFα, CD80, and MHC class II, leading to T cell activation. Consistently, we confirmed that intravenous injection of CXCR5 high B cells enhanced hepatic inflammation in MASH model. Ultimately, this study elucidates the role and mechanisms of CXCR5 high B cells in advancing MASH progression.
- Open Access
Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein
SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. It remains unclear how the continuous evolution of the virus impacts the breadth of the induced GC B cell response. Using ultrasound-guided fine needle aspiration, we examined draining lymph nodes of nine healthy adults following bivalent booster immunization. We show that 77.8% of the B cell clones in the GC expressed as representative monoclonal antibodies recognized the spike protein, with a third (37.8%) of these targeting the receptor binding domain (RBD). Strikingly, only one RBD-targeting mAb, mAb-52, neutralized all tested SARS- CoV-2 strains, including the recent KP.2 variant. mAb-52 utilizes the IGHV3-66 public clonotype, protects hamsters challenged against the EG.5.1 variant and targets the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Finally, we show that the remarkable breadth of mAb-52 is due to the somatic hypermutations accumulated within vaccine-induced GC reaction. One Sentence Summary Booster SARS-CoV-2 mRNA vaccine recruits and broadens GC B cell responses targeting a highly conserved site on receptor binding domain of spike glycoprotein.
Open AccessDefining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein
SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. It remains unclear how the continuous evolution of the virus impacts the breadth of the induced GC B cell response. Using ultrasound-guided fine needle aspiration, we examined draining lymph nodes of nine healthy adults following bivalent booster immunization. We show that 77.8% of the B cell clones in the GC expressed as representative monoclonal antibodies recognized the spike protein, with a third (37.8%) of these targeting the receptor binding domain (RBD). Strikingly, only one RBD-targeting mAb, mAb-52, neutralized all tested SARS- CoV-2 strains, including the recent KP.2 variant. mAb-52 utilizes the IGHV3-66 public clonotype, protects hamsters challenged against the EG.5.1 variant and targets the class I/II RBD epitope, closely mimicking the binding footprint of ACE2. Finally, we show that the remarkable breadth of mAb-52 is due to the somatic hypermutations accumulated within vaccine-induced GC reaction. One Sentence Summary Booster SARS-CoV-2 mRNA vaccine recruits and broadens GC B cell responses targeting a highly conserved site on receptor binding domain of spike glycoprotein.
- 20 August 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (9) , 1731-1741
CD4+ T cells exhibit distinct transcriptional phenotypes in the lymph nodes and blood following mRNA vaccination in humans
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mRNA vaccination induce robust CD4+ T cell responses. Using single-cell transcriptomics, here, we evaluated CD4+ T cells specific for the SARS-CoV-2 spike protein in the blood and draining lymph nodes (dLNs) of individuals 3 months and 6 months after vaccination with the BNT162b2 mRNA vaccine. We analyzed 1,277 spike-specific CD4+ T cells, including 238 defined using Trex, a deep learning-based reverse epitope mapping method to predict antigen specificity. Human dLN spike-specific CD4+ follicular helper T (TFH) cells exhibited heterogeneous phenotypes, including germinal center CD4+ TFH cells and CD4+IL-10+ TFH cells. Analysis of an independent cohort of SARS-CoV-2-infected individuals 3 months and 6 months after infection found spike-specific CD4+ T cell profiles in blood that were distinct from those detected in blood 3 months and 6 months after BNT162b2 vaccination. Our findings provide an atlas of human spike-specific CD4+ T cell transcriptional phenotypes in the dLNs and blood following SARS-CoV-2 vaccination or infection.
- 20 August 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (9) , 1731-1741
CD4+ T cells exhibit distinct transcriptional phenotypes in the lymph nodes and blood following mRNA vaccination in humans
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mRNA vaccination induce robust CD4+ T cell responses. Using single-cell transcriptomics, here, we evaluated CD4+ T cells specific for the SARS-CoV-2 spike protein in the blood and draining lymph nodes (dLNs) of individuals 3 months and 6 months after vaccination with the BNT162b2 mRNA vaccine. We analyzed 1,277 spike-specific CD4+ T cells, including 238 defined using Trex, a deep learning-based reverse epitope mapping method to predict antigen specificity. Human dLN spike-specific CD4+ follicular helper T (TFH) cells exhibited heterogeneous phenotypes, including germinal center CD4+ TFH cells and CD4+IL-10+ TFH cells. Analysis of an independent cohort of SARS-CoV-2-infected individuals 3 months and 6 months after infection found spike-specific CD4+ T cell profiles in blood that were distinct from those detected in blood 3 months and 6 months after BNT162b2 vaccination. Our findings provide an atlas of human spike-specific CD4+ T cell transcriptional phenotypes in the dLNs and blood following SARS-CoV-2 vaccination or infection.
- Open Access
- 27 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (8)
Maturation of germinal center B cells after influenza virus vaccination in humans
Germinal centers (GC) are microanatomical lymphoid structures where affinity-matured memory B cells and long-lived bone marrow plasma cells are primarily generated. It is unclear how the maturation of B cells within the GC impacts the breadth and durability of B cell responses to influenza vaccination in humans. We used fine needle aspiration of draining lymph nodes to longitudinally track antigen-specific GC B cell responses to seasonal influenza vaccination. Antigen-specific GC B cells persisted for at least 13 wk after vaccination in two out of seven individuals. Monoclonal antibodies (mAbs) derived from persisting GC B cell clones exhibit enhanced binding affinity and breadth to influenza hemagglutinin (HA) antigens compared with related GC clonotypes isolated earlier in the response. Structural studies of early and late GC-derived mAbs from one clonal lineage in complex with H1 and H5 HAs revealed an altered binding footprint. Our study shows that inducing sustained GC reactions after influenza vaccination in humans supports the maturation of responding B cells.
- 27 June 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (8)
Open AccessMaturation of germinal center B cells after influenza virus vaccination in humans
Germinal centers (GC) are microanatomical lymphoid structures where affinity-matured memory B cells and long-lived bone marrow plasma cells are primarily generated. It is unclear how the maturation of B cells within the GC impacts the breadth and durability of B cell responses to influenza vaccination in humans. We used fine needle aspiration of draining lymph nodes to longitudinally track antigen-specific GC B cell responses to seasonal influenza vaccination. Antigen-specific GC B cells persisted for at least 13 wk after vaccination in two out of seven individuals. Monoclonal antibodies (mAbs) derived from persisting GC B cell clones exhibit enhanced binding affinity and breadth to influenza hemagglutinin (HA) antigens compared with related GC clonotypes isolated earlier in the response. Structural studies of early and late GC-derived mAbs from one clonal lineage in complex with H1 and H5 HAs revealed an altered binding footprint. Our study shows that inducing sustained GC reactions after influenza vaccination in humans supports the maturation of responding B cells.
- Open Access
- 1 January 2024
- Published by XMLink in Immune Network
- Vol. 24 (4) , e28
Germinal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination
Kim W. Immune Netw. 2024 Jun;24(4):e28. https://doi.org/10.4110/in.2024.24.e28
- 1 January 2024
- Published by XMLink in Immune Network
- Vol. 24 (4) , e28
Open AccessGerminal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination
Kim W. Immune Netw. 2024 Jun;24(4):e28. https://doi.org/10.4110/in.2024.24.e28
- Top Cited PapersOpen Access
- 3 April 2023
- Published by Springer Nature in Nature
- Vol. 617 (7961) , 592-598
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines1–4. SARS-CoV-2 booster immunizations in humans primarily recruit pre-existing memory B cells (MBCs)5–9. It remains unclear, however, whether the additional doses induce germinal centre (GC) reactions where reengaged B cells can further mature and whether variant-derived vaccines can elicit responses to variant-specific epitopes. Here, we show that boosting with either the original monovalent SARS-CoV-2 or bivalent B.1.351/B.1.617.2 (Beta/Delta) mRNA vaccines induces robust spike-specific GC B cell responses in humans. The GC response persisted for at least eight weeks, leading to significantly more mutated antigen-specific bone marrow plasma cell and MBC compartments. All MBC-derived spike-binding monoclonal antibodies (mAbs, n=766) isolated from individuals boosted with either the original SARS-CoV-2 spike, bivalent Beta/Delta, or a monovalent Omicron BA.1-based vaccine recognized the original SARS-CoV-2 spike protein. Nonetheless, by using a more targeted sorting approach we isolated mAbs that recognized the BA.1 spike protein but not the original SARS-CoV-2 spike from the mRNA-1273.529 boosted individuals. The latter mAbs were less mutated and recognized novel epitopes within the spike protein, suggesting a naïve B cell origin. Thus, SARS-CoV-2 booster immunizations in humans induce robust GC B cell responses and can generate de novo B cell responses targeting variant-specific epitopes.
- 3 April 2023
- Published by Springer Nature in Nature
- Vol. 617 (7961) , 592-598
Top Cited PapersOpen AccessSARS-CoV-2 Omicron boosting induces de novo B cell response in humans
The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines1–4. SARS-CoV-2 booster immunizations in humans primarily recruit pre-existing memory B cells (MBCs)5–9. It remains unclear, however, whether the additional doses induce germinal centre (GC) reactions where reengaged B cells can further mature and whether variant-derived vaccines can elicit responses to variant-specific epitopes. Here, we show that boosting with either the original monovalent SARS-CoV-2 or bivalent B.1.351/B.1.617.2 (Beta/Delta) mRNA vaccines induces robust spike-specific GC B cell responses in humans. The GC response persisted for at least eight weeks, leading to significantly more mutated antigen-specific bone marrow plasma cell and MBC compartments. All MBC-derived spike-binding monoclonal antibodies (mAbs, n=766) isolated from individuals boosted with either the original SARS-CoV-2 spike, bivalent Beta/Delta, or a monovalent Omicron BA.1-based vaccine recognized the original SARS-CoV-2 spike protein. Nonetheless, by using a more targeted sorting approach we isolated mAbs that recognized the BA.1 spike protein but not the original SARS-CoV-2 spike from the mRNA-1273.529 boosted individuals. The latter mAbs were less mutated and recognized novel epitopes within the spike protein, suggesting a naïve B cell origin. Thus, SARS-CoV-2 booster immunizations in humans induce robust GC B cell responses and can generate de novo B cell responses targeting variant-specific epitopes.
- Open Access
- 11 January 2023
- Published by Elsevier in Journal of Clinical Virology Plus
- Vol. 3 (1) , 100135
A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
- 11 January 2023
- Published by Elsevier in Journal of Clinical Virology Plus
- Vol. 3 (1) , 100135
Open AccessA simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
- Open Access
- 1 July 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (27)
Differentiation and homeostasis of effector Treg cells are regulated by inositol polyphosphates modulating Ca2+influx
Activated Foxp3+regulatory T (Treg) cells differentiate into effector Treg (eTreg) cells to maintain peripheral immune homeostasis and tolerance. T cell receptor (TCR)–mediated induction and regulation of store-operated Ca2+entry (SOCE) is essential for eTreg cell differentiation and function. However, SOCE regulation in Treg cells remains unclear. Here, we show that inositol polyphosphate multikinase (IPMK), which generates inositol tetrakisphosphate and inositol pentakisphosphate, is a pivotal regulator of Treg cell differentiation downstream of TCR signaling. IPMK is highly expressed in TCR-stimulated Treg cells and promotes a TCR-induced Treg cell program. IPMK-deficient Treg cells display aberrant T cell activation and impaired differentiation into RORγt+Treg cells and tissue-resident Treg cells. Mechanistically, IPMK controls the generation of higher-order inositol phosphates, thereby promoting Ca2+mobilization and Treg cell effector functions. Our findings identify IPMK as a critical regulator of TCR-mediated Ca2+influx and highlight the importance of IPMK in Treg cell-mediated immune homeostasis.
- 1 July 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (27)
Open AccessDifferentiation and homeostasis of effector Treg cells are regulated by inositol polyphosphates modulating Ca2+influx
Activated Foxp3+regulatory T (Treg) cells differentiate into effector Treg (eTreg) cells to maintain peripheral immune homeostasis and tolerance. T cell receptor (TCR)–mediated induction and regulation of store-operated Ca2+entry (SOCE) is essential for eTreg cell differentiation and function. However, SOCE regulation in Treg cells remains unclear. Here, we show that inositol polyphosphate multikinase (IPMK), which generates inositol tetrakisphosphate and inositol pentakisphosphate, is a pivotal regulator of Treg cell differentiation downstream of TCR signaling. IPMK is highly expressed in TCR-stimulated Treg cells and promotes a TCR-induced Treg cell program. IPMK-deficient Treg cells display aberrant T cell activation and impaired differentiation into RORγt+Treg cells and tissue-resident Treg cells. Mechanistically, IPMK controls the generation of higher-order inositol phosphates, thereby promoting Ca2+mobilization and Treg cell effector functions. Our findings identify IPMK as a critical regulator of TCR-mediated Ca2+influx and highlight the importance of IPMK in Treg cell-mediated immune homeostasis.
- Open Access
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7) , S-592-592
Su1481: IMPACT OF IMMUNOSUPPRESSIVE THERAPIES ON ANTIBODY DECAY FOLLOWING MRNA VACCINATION TO SARS-COV-2 IN A PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7) , S-592-592
Open AccessSu1481: IMPACT OF IMMUNOSUPPRESSIVE THERAPIES ON ANTIBODY DECAY FOLLOWING MRNA VACCINATION TO SARS-COV-2 IN A PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES